98%
921
2 minutes
20
Aims: Traditional atrial fibrillation (AF) recurrence after catheter ablation is reported as a binary outcome. However, a paradigm shift towards a more granular definition, considering arrhythmic or symptomatic burden, is emerging. We hypothesize that ablation reduces AF burden independently of conventional recurrence status in patients with persistent AF, correlating with symptom burden reduction.
Methods And Results: Ninety-eight patients with persistent AF from the DECAAF II trial with pre-ablation follow-up were included. Patients recorded daily single-lead electrocardiogram (ECG) strips, defining AF burden as the proportion of AF days among total submitted ECG days. The primary outcome was atrial arrhythmia recurrence. The AF severity scale was administered pre-ablation and at 12 months post-ablation. At follow-up, 69 patients had atrial arrhythmia recurrence and 29 remained in sinus rhythm. These patients were categorized into a recurrence (n = 69) and a no-recurrence group (n = 29). Both groups had similar baseline characteristics, but recurrence patients were older (P = 0.005), had a higher prevalence of hyperlipidaemia (P = 0.007), and had a larger left atrial (LA) volume (P = 0.01). There was a reduction in AF burden in the recurrence group when compared with their pre-ablation burden (65 vs. 15%, P < 0.0001). Utah Stage 4 fibrosis and diabetes predicted less improvement in AF burden. The symptom severity score at 12 months post-ablation was significantly reduced compared with the pre-ablation score in the recurrence group, and there was a significant correlation between the reduction in symptom severity score and the reduction in AF burden (R = 0.39, P = 0.001).
Conclusion: Catheter ablation reduces AF burden, irrespective of arrhythmia recurrence post-procedure. There is a strong correlation between AF burden reduction and symptom improvement post-ablation. Notably, elevated LA fibrosis impedes AF burden decrease following catheter ablation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11077606 | PMC |
http://dx.doi.org/10.1093/europace/euae104 | DOI Listing |
Scand J Med Sci Sports
September 2025
Department of Dermatology and Allergy Biederstein, School of Medicine and Health, TUM University Hospital Rechts der Isar, Munich, Germany.
In wheat allergy dependent on augmentation factors (WALDA), allergic reactions occur when wheat ingestion is combined with exercise or rarely other augmentation factors. We analyzed clinical characteristics and disease burden in recreationally active and trained individuals with WALDA diagnosed by oral challenge test. Clinical characteristics, serological data, and quality of life (QOL) questionnaires were analyzed and completed with follow-up interviews.
View Article and Find Full Text PDFAlzheimers Dement
September 2025
Department of Neurology, Beijing TianTan Hospital, Capital Medical University, Beijing, China.
Cognitive impairment and dementia, including Alzheimer's disease (AD), pose a global health crisis, necessitating non-invasive biomarkers for early detection. This review highlights the retina, an accessible extension of the central nervous system (CNS), as a window to cerebral pathology through structural, functional, and molecular alterations. By synthesizing interdisciplinary evidence, we identify retinal biomarkers as promising tools for early diagnosis and risk stratification.
View Article and Find Full Text PDFMuscle Nerve
September 2025
Department of Neurology, Seoul Hospital, Ewha Womans University College of Medicine, Seoul, South Korea.
Introduction/aims: There is a lack of up-to-date information on the burden of motor neuron diseases (MNDs) in the United States (US). This study aimed to estimate trends in the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) for MNDs in the US from 1990 to 2021.
Methods: We performed a secondary analysis of MNDs in the US using estimates of prevalence, incidence, and mortality obtained from analyses of the Global Burden of Disease 2021 dataset.
Mult Scler
September 2025
Neuroimaging Unit, Neuroimmunology Division, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, VA Medical Center, TN Valley Healthcare System, Nashville, TN, USA.
Background: There is limited knowledge on the post-glymphatic structures such as the parasagittal dural (PSD) space and the arachnoid granulations (AGs) in multiple sclerosis (MS).
Objectives: To evaluate differences in volume and macromolecular content of PSD and AG between people with newly diagnosed MS (pwMS), clinically isolated syndrome (pwCIS), or radiologically isolated syndrome (pwRIS) and healthy controls (HCs) and their associations with clinical and radiological disease measures.
Methods: A total of 69 pwMS, pwCIS, pwRIS, and HCs underwent a 3.
New Microbes New Infect
October 2025
Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Background: Dengue is a mosquito-borne viral infection with growing global impact, including international travellers travelling to and from endemic regions. This systematic literature review aimed to assess the clinical and economic burden of dengue in travellers from non-endemic countries.
Methods: This systematic review was conducted following the PRISMA guidelines to assess the incidence, prevalence, mortality, healthcare resource use, and costs of dengue fever in travellers between non-endemic and endemic regions.